How appropriate use criteria for PSMA-PET imaging optimize patient careFebruary 2nd 2022
In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Appropriate use criteria for PSMA-PET imaging will help guide cliniciansJanuary 27th 2022
“This is an attempt to provide the clinicians with the most recent available data and evidence, and therefore, tell them how this particular imaging…may affect their decision making for the treatment and management of their patients,” says Hossein Jadvar, MD, PhD.
How appropriate use criteria was created for PSMA-PET imagingJanuary 20th 2022
“There is a rather extensive process of how to develop appropriate use criteria. It is primarily based on literature and evidence, systematic reviews, and analysis of those data,” says Hossein Jadvar, MD, PhD.
Why lutetium-177–PSMA-617 is highly sought after by patients with mCRPCDecember 21st 2021
The impact of the VISION trial, a study investigating prostate-specific membrane antigen (PSMA)-targeted therapy for advanced prostate cancer, was discussed in a talk presented by Michael J. Morris, MD, at the 2021 Society of Urologic Oncology Annual Meeting.
Trial of novel PSMA-PET imaging agent in prostate cancer hits enrollment milestoneDecember 9th 2021
The PROPELLER trial is exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy.
Current clinical trials examining LuPSMANovember 18th 2021
“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Dr. Bander gives an overview of PSMA-PET imaging innovationsNovember 16th 2021
“It's very clear that PSMA-PET imaging is having…a transformative impact on our ability to image metastatic disease, in that it is much more sensitive than we've had for the last 50 plus years—and also, 98% specific,” says Neil H. Bander, MD.
Goals of ProsTIC's theranostics research in prostate cancerNovember 15th 2021
“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
Dr. Hofman on the potential of LuPSMA in advanced prostate cancerNovember 11th 2021
“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
PSMA-PET imaging to be available at all US GenesisCare CentersNovember 2nd 2021
The oncology provider will enable patient access to the PSMA-PET imaging agent piflufolastat F 18, which the FDA approved in May 2021 for identifying suspected metastasis or recurrence of prostate cancer.
Adding PSMA PET/CT imaging to mpMRI improves detection of significant prostate cancerOctober 28th 2021
"Combining mpMRI and 68Ga-PSMA PET/CT in a primary diagnostic setting could better identify where to target on biopsy, increasing the diagnostic yield, improving concordance with underlying tumor grade and therefore improving management recommendations," the authors wrote.
Transitional Zone sampling can be spared in some men with suspicious prostate cancer lesions on mpMRIOctober 25th 2021
“This zone-dependent biopsy strategy warrants prospective evaluation to optimize the extent of systematic biopsies in presence of suspicious mpMRI lesions,” the authors wrote.
PSMA-PET imaging may miss small pelvic nodal metastases in men with prostate cancerOctober 19th 2021
"Clinicians taking care of patients with high-risk prostate cancer being assessed for prostatectomy can use a positive [PSMA] PET scan as a true positive, whereas a negative scan cannot be used to exclude disease or inform nodal dissection," wrote Joseph Osborne, MD, PhD, and colleagues.
PSMA targeted CAR T-cell therapy shows antitumor activity in mCRPCSeptember 1st 2021
"This is the first time that I have seen such impressive responses with an immunotherapy product. The responses of my patients in the trial are far beyond my expectations," said study investigator Susan F. Slovin, MD, PhD.